Given the suboptimal anti-tumor activity of single agent ICPIs in EP-NECs, approaches with dual ICPIs that target programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have been evaluated. The gene discussed is CTLA4; the disease is neoplasm.